Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Respirology2021Vol. 27(4), pp. 301–310
Citations Over TimeTop 10% of 2021 papers
Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M. S. Cheng, Chunke Chen, Kin On Kwok, Karen Yiu, Tat‐On Chan, Maireid Bull, Kwun Cheung Ling, Zixi Dai, Susanna S. Ng, Grace Lui, Chao Wu, Gaya K. Amarasinghe, Daisy W. Leung, Samuel Yeung Shan Wong, Sophie A. Valkenburg, Malik Peiris, David S.C. Hui
Abstract
Vaccination with BNT162b2 induces stronger humoral responses than CoronaVac. CoronaVac induces higher CD4+ and CD8+ T-cell responses to the structural protein than BNT162b2.
Related Papers
- → Chilblain‐like lesions after BNT162b2 mRNA COVID‐19 vaccine: a case report suggesting that ‘COVID toes’ are due to the immune reaction to SARS‐CoV‐2(2021)26 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → ОПЫТ ИССЛЕДОВАНИЯ СЕРОПРЕВАЛЕНТНОСТИ К ВИРУСУ SARS-CoV-2 НАСЕЛЕНИЯ ИРКУТСКОЙ ОБЛАСТИ В ПЕРИОД ВСПЫШКИ COVID-19(2020)2 cited
- → Особенности сахароснижающей фармакотерапии у пациентов с SARS-CoV-2 (COVID-19)(2021)